Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisatracurium besilate, quantity: 67 mg (equivalent: cisatracurium, qty 50 mg) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisatracurium besilate, quantity: 13.4 mg (equivalent: cisatracurium, qty 10 mg) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 2 mg in 1 ml - cisatracurium besylate injection is an intermediate-onset/intermediate-duration neuromuscular blocking agent indicated for inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the icu. cisatracurium is contraindicated in patients with known hypersensitivity to the product and its components.  the 10 ml multiple dose vials of cisatracurium is contraindicated for use in premature infants because the formulation contains benzyl alcohol (see warnings and  precautions,  pediatric use ).

United States - English - NLM (National Library of Medicine)

sandoz inc - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 2 mg in 1 ml - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. risk summary there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal studies conducted in rats administered cisatracurium besylate during organogenesis (gestational day 6 to 15) found no evidence of fetal harm at 0.8 times (ventilated rats) the exposure from a human starting iv bolus dose of 0.2 mg/kg (see data) . the estimated background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, r

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - cisatracurium besilate -

Ireland - English - HPRA (Health Products Regulatory Authority)

as kalceks - cisatracurium besilate; cisatracurium - solution for injection/infusion - 2 milligram(s)/millilitre - cisatracurium

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - cisatracurium besilate -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - cisatracurium besilate -